Get the Stockscreener App
2.15
4.44%
-0.10
After Hours:
2.04
-0.11
-5.12%
Lakeshore Biopharma Co Ltd stock is traded at $2.15, with a volume of 35,686.
It is down -4.44% in the last 24 hours and down -60.55% over the past month.
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
See More
Previous Close:
$2.25
Open:
$2.05
24h Volume:
35,686
Relative Volume:
1.79
Market Cap:
$41.02M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-20.07%
1M Performance:
-60.55%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.88
$2.26
1-Week Range:
$1.88
$2.90
52-Week Range:
$1.88
$9.988
Lakeshore Biopharma Co Ltd Stock (LSB) Company Profile
Name
Lakeshore Biopharma Co Ltd
Sector
Industry
Phone
-
Address
-
Lakeshore Biopharma Co Ltd Stock (LSB) Latest News
Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66% - Simply Wall St
LakeShore Biopharma regains Nasdaq compliance By Investing.com - Investing.com Canada
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - StreetInsider.com
LakeShore Biopharma regains Nasdaq compliance - Investing.com India
LakeShore Biopharma Advances with Rabies Vaccine Trial - Yahoo Finance
LakeShore Biopharma to test simplified rabies vaccine regimen By Investing.com - Investing.com Australia
LakeShore Biopharma's YSJA Rabies Vaccine Heads To Phase III Trial - Contract Pharma
LakeShore Biopharma to test simplified rabies vaccine regimen - Investing.com
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine - StockTitan
YS Biopharma (YSB) Stock Price, News & Analysis - MarketBeat
LakeShore Biopharma projects steady growth for FY2025 By Investing.com - Investing.com Australia
LakeShore Biopharma projects steady growth for FY2025 - Investing.com
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance - The Manila Times
LakeShore Biopharma Co., Ltd Provides Financial Guidance for the Half Year of Fiscal Year of 2025 and Full Year of Fiscal Year 2025 Ending on March 31, 2025 - Marketscreener.com
LSB’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Metric Deep Dive: Understanding LakeShore Biopharma Co Ltd. (LSB) Through its Ratios - The Dwinnex
LakeShore Biopharma Updates Corporate Framework - TipRanks
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation - Kilgore News Herald
Life & Banc Split (TSE:LBS) Sets New 52-Week High at $8.46 - MarketBeat
Multibagger Stock under Rs 20: After stock split, Ok Play allots equities upon warrants conversion - ET Now
Roadwork returns on DLSD: What to know - WBBM
Carvela steps into Lakeside Village - Doncaster Free Press
LakeShore Biopharma Calls for Shareholder Vote on Stock Compliance - TipRanks
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 - The Manila Times
LakeShore changes CEO with new executive appointments - The Pharma Letter
LakeShore Biopharma names Xu Wang as new CEO - Investing.com India
LakeShore Biopharma names Xu Wang as new CEO By Investing.com - Investing.com Canada
LakeShore Biopharma Announces Leadership Transitions - Kilgore News Herald
Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Update - Defense World
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 - The Manila Times
Short Interest in Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Rises By 20.1% - Defense World
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - Longview News-Journal
LakeShore Biopharma Insider Ups Holding By 3,083% During Year - Simply Wall St
ROSEN, LEADING INVESTOR COUNSEL, Encourages YS Biopharma Co., Ltd. f/k/a Summit Healthcare Acquisition Corp. Investors to Inquire About Securities Class Action InvestigationYS, SMIH - Marketscreener.com
LakeShore Biopharma (NASDAQ:LSB) Stock Quotes, Forecast and News Summary - Benzinga
LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough - Simply Wall St
LakeShore Biopharma Announces Executive ReshuffleTipRanks.com - TipRanks
The Hunt for Virus Treatments Continues Post Covid-19 - Exeter Lakeshore Times-Advance
Exploring High Insider Ownership In US Growth Companies - Simply Wall St
LakeShore Biopharma Co., Ltd (NASDAQ:LSB): Are Analysts Optimistic? - Simply Wall St
LakeShore Biopharma Co., Ltd (NASDAQ:LSB): When Will It Breakeven? - Yahoo Finance
Does Dun & Bradstreet Holdings (NYSE:DNB) Have A Healthy Balance Sheet? - Simply Wall St
YS, SMIH INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages YS Biopharma Co., Ltd. f/k/a ... - Marketscreener.com
YS Biopharma announces name change to 'LakeShore Biopharma'TipRanks.com - TipRanks
YS Biopharma to change legal name to LakeShore Biopharma (NASDAQ:YS) - Seeking Alpha
YS Biopharma Announces Name Change to LakeShore Biopharma USAEnglish - PR Newswire
YS Biopharma announces name change to ‘LakeShore Biopharma’ - TipRanks
YS Biopharma Announces Results of Extraordinary General Meeting - Thailand Business News
YS Biopharma Approves Major Corporate ChangesTipRanks.com - TipRanks
YS Biopharma Announces Results of Extraordinary General Meeting APACEnglish - PR Newswire
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer - PR Newswire
Lakeshore Biopharma Co Ltd Stock (LSB) Financials Data
There is no financial data for Lakeshore Biopharma Co Ltd (LSB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):